ULTRASE MT20 FOR CORRECTION OF STEATORRHEA IN PATIENTS WITH CYSTIC FIBROSIS

ULTRASE MT20 用于纠正囊性纤维化患者的脂肪泻

• 批准号: 7604922
• 负责人: RICHARD C AHRENS
• 金额: $ 2.21万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604922
• 关键词: Collection; Computer Retrieval of Information on Scientific Projects Database; Cross-Over Studies; Data; Double-Blind Method; Enzymes; Evaluable Disease; Fatty acid glycerol esters; Feces; Funding; Grant; Hour; Inpatients; Institution; Marketing; Measures; Outpatients; Pancreatic enzyme; Phase; Placebo Control; Placebos; Randomized; Research; Research Personnel; Resources; Safety; Screening procedure; Site; Source; Steatorrhea; United States Food and Drug Administration; United States National Institutes of Health; cystic fibrosis patients; day

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase III, randomized, double-blind, placebo-controlled crossover study evaluating the safety and efficacy of Ultrase MT20 (pancreatic enzyme product). The study consists of an outpatient screening phase of up to 11 days, 2 study enzyme stabilization periods and 2 inpatient stays lasting 6-7 days each for comparing active study enzymes to placebo in amount of fecal fat measured during a 72-hour stool collection. A sufficient numer of CF subjects will be randomized in order to get a total of 24 evaluable subjects from approximately 8 sites. This is to meet the FDA mandate that after 2008, all enzyme products must submit efficacy/safety data or be pulled from the market.

这个子项目是众多研究子项目之一